# AZD4512

Source: https://onco.cc/drugs/azd4512/  
OnCo record `azd4512` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD4512 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for hodgkin lymphoma, aimed at CD22.

## Summary

AZD4512 is an antibody-drug conjugate developed by AstraZeneca. Its target is CD22 (the sponsor names CD22). The sponsor states: An antibody-drug conjugate targeting CD22, administered by intravenous infusion; specific payload/mechanism detail beyond CD22 targeting was not stated on the fetched page. ClinicalTrials.gov describes the intervention as: AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT07123454, plans to enrol 91 participants with primary completion expected 2028-03-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: An antibody-drug conjugate targeting CD22, administered by intravenous infusion; specific payload/mechanism detail beyond CD22 targeting was not stated on the fetched page.

## Sources

- ClinicalTrials.gov: trials of AZD4512: https://clinicaltrials.gov/search?intr=AZD4512

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- targets: [CD22](https://onco.cc/targets/cd22/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom](https://onco.cc/trials/nct07123454/), [Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia](https://onco.cc/trials/nct07109219/)

---
JSON: https://onco.cc/api/v1/entities/azd4512.json